$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000117891313002087 Filed on July 17, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$660.0K	$500.0K	$400.0K
YoY Change	65.0%	72.41%	33.33%
% of Gross Profit
Research & Development	$290.0K	$835.6K	$540.0K
YoY Change	-46.3%	234.59%	86.21%
% of Gross Profit
Depreciation & Amortization	$10.00K	$0.00	-$10.00K
YoY Change	-200.0%	-100.0%	-200.0%
% of Gross Profit
Operating Expenses	$960.0K	$835.6K	$940.0K
YoY Change	2.13%	234.59%	59.32%
Operating Profit		-$1.335M
YoY Change		146.97%
Interest Expense	-$40.00K	$80.00K	-$1.870M
YoY Change	-97.86%	-900.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.000M	-$1.256M	-$2.950M
YoY Change	-66.1%	128.27%	268.75%
Income Tax	-$210.0K		$90.00K
% Of Pretax Income
Net Earnings	-$790.0K	-$1.256M	-$3.040M
YoY Change	-74.01%	128.27%	294.81%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$104.4K	-$174.5K	-$508.4K
COMMON SHARES
Basic Shares Outstanding	7.901M shares	7.223M shares	70.45M
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.480M	$4.230M	$5.090M
YoY Change	66.6%	95.83%	37.57%
Cash & Equivalents	$2.272M	$1.105M	$4.431M
Short-Term Investments	$6.200M	$3.130M	$650.0K
Other Short-Term Assets	$30.21K	$80.00K	$36.66K
YoY Change	-17.6%	100.0%	83.29%
Inventory
Prepaid Expenses		$62.30K	$2.307K
Receivables		$333.7K	$87.69K
Other Receivables	$58.00K	$178.8K	$84.64K
Total Short-Term Assets	$8.644M	$4.824M	$5.276M
YoY Change	63.82%	96.21%	23.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.000K	$5.730K	$4.768K
YoY Change	25.84%	170.16%	-72.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$10.00K	$10.00K
YoY Change	-100.0%	0.0%	0.0%
Other Assets	$10.00K	$10.00K	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$16.00K	$22.52K	$18.38K
YoY Change	-12.93%	42.62%	-56.1%
TOTAL ASSETS
Total Short-Term Assets	$8.644M	$4.824M	$5.276M
Total Long-Term Assets	$16.00K	$22.52K	$18.38K
Total Assets	$8.660M	$4.846M	$5.295M
YoY Change	63.56%	95.87%	22.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$450.0K	$400.0K	$600.0K
YoY Change	-25.0%	29.03%	57.89%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$498.0K	$446.0K	$644.4K
YoY Change	-22.72%	25.34%	46.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$30.00K	$240.0K	$870.0K
YoY Change	-96.55%	60.0%	443.75%
Total Long-Term Liabilities	$31.00K	$241.1K	$872.4K
YoY Change	-96.45%	64.17%	442.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$498.0K	$446.0K	$644.4K
Total Long-Term Liabilities	$31.00K	$241.1K	$872.4K
Total Liabilities	$529.0K	$687.1K	$1.517M
YoY Change	-65.12%	36.68%	151.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$22.12M	-$21.33M	-$17.89M
YoY Change	23.65%	28.81%	22.99%
Common Stock	$29.95M	$25.36M	$21.67M
YoY Change	38.22%	36.95%	18.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.131M	$4.159M	$3.778M
YoY Change
Total Liabilities & Shareholders Equity	$8.660M	$4.846M	$5.295M
YoY Change	63.56%	95.87%	22.4%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q3
OPERATING ACTIVITIES
Net Income	-$790.0K	-$1.256M	-$3.040M
YoY Change	-74.01%	128.27%	294.81%
Depreciation, Depletion And Amortization	$10.00K	$0.00	-$10.00K
YoY Change	-200.0%	-100.0%	-200.0%
Cash From Operating Activities	-$280.0K	-$1.050M	-$340.0K
YoY Change	-17.65%	19.32%	-20.93%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$2.920M	$110.0K	$20.00K
YoY Change	-14700.0%	-67.65%	-300.0%
Cash From Investing Activities	-$2.930M	$110.0K	$20.00K
YoY Change	-14750.0%	-67.65%	-300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.370M	0.000	3.490M
YoY Change	25.21%
NET CHANGE
Cash From Operating Activities	-280.0K	-1.050M	-340.0K
Cash From Investing Activities	-2.930M	110.0K	20.00K
Cash From Financing Activities	4.370M	0.000	3.490M
Net Change In Cash	1.160M	-940.0K	3.170M
YoY Change	-63.41%	74.07%	-820.45%
FREE CASH FLOW
Cash From Operating Activities	-$280.0K	-$1.050M	-$340.0K
Capital Expenditures	-$10.00K	$0.00	$0.00
Free Cash Flow	-$270.0K	-$1.050M	-$340.0K
YoY Change	-20.59%	19.32%	-20.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	917809	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	3778013	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2009	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	117174	USD
CY2010	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	116944	USD
CY2011	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	26733	USD
	dei	Document Period End Date DocumentPeriodEndDate	2013-05-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001176309
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7900829	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	140477	USD
	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	177782	USD
CY2008	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	203982	USD
CY2012	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	70292	USD
	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	8437	USD
CY2008	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2009	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2010	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2011	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3782	USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature	108000	USD
	ormp	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Change In Fair Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetChangeInFairValue	113165	USD
	ormp	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue	-44699	USD
	ormp	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Exchange Of Warrants FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisExchangeOfWarrants	620827	USD
	ormp	Finders Fee Shares FindersFeeShares	16397	shares
CY2011	ormp	Finders Fee Shares FindersFeeShares	13871	shares
	ormp	Imputed Interest Expense ImputedInterestExpense		USD
	ormp	Imputed Interest Expense ImputedInterestExpense		USD
	ormp	Imputed Interest Expense ImputedInterestExpense	23559	USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances	6061	USD
CY2008	ormp	Receipts On Account Of Shares And Warrants ReceiptsOnAccountOfSharesAndWarrants	6061	USD
	ormp	Shares Cancelled Value SharesCancelledValue		USD
	ormp	Shares To Be Issued For Services Rendered SharesToBeIssuedForServicesRendered	93713	USD
	ormp	Shares To Be Issued For Services Rendered SharesToBeIssuedForServicesRendered		USD
	ormp	Shares To Be Issued For Services Rendered SharesToBeIssuedForServicesRendered	93713	USD
	ormp	Stock Issued During Period Value Marketable Securities StockIssuedDuringPeriodValueMarketableSecurities	628630	USD
	ormp	Stock Issued During Period Value Offering Costs StockIssuedDuringPeriodValueOfferingCosts		USD
	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	98750	USD
CY2008	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	116110	USD
CY2009	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	152928	USD
CY2010	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	249850	USD
CY2011	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	227569	USD
CY2012	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	107860	USD
	ormp	Stock Issued During Period Value Services To Be Rendered StockIssuedDuringPeriodValueServicesToBeRendered	93713	USD
CY2009	ormp	Stock Issued During Period Value Services To Be Rendered StockIssuedDuringPeriodValueServicesToBeRendered	203699	USD
CY2012	ormp	Stock Issued During Period Value Shares To Be Issued StockIssuedDuringPeriodValueSharesToBeIssued	25093	USD
	ormp	Warrants Exchanged WarrantsExchanged	296982	USD
	ormp	Warrants Exchanged WarrantsExchanged		USD
	ormp	Warrants Exchanged WarrantsExchanged	296982	USD
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	398772	USD
CY2012Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	597173	USD
CY2013Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2012Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	333719	USD
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	87691	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	131924	USD
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	25273343	USD
CY2012Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	21589715	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18991	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	487034	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1968547	USD
CY2008	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	459467	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	436025	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	690882	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	502593	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	200866	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	917809	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	USD
CY2013Q2	us-gaap	Assets Assets	4846300	USD
CY2012Q3	us-gaap	Assets Assets	5294851	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	4823783	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	5276476	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1104897	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4430740	USD
CY2002Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1299865	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1513365	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3325843	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-213500	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1104897	USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16666667	shares
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16666667	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16700000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7226423	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6674068	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86500000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7200000	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7226423	shares
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6674068	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86500000	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7200000	shares
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	86702	USD
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	80075	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3309044	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2014259	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1368925	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-566234	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21200821	USD
	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty	18991	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	917809	USD
CY2013Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	2323947	USD
CY2012Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	454381	USD
	us-gaap	Depreciation Depreciation	3697	USD
	us-gaap	Depreciation Depreciation	17384	USD
	us-gaap	Depreciation Depreciation	124541	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	44699	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-98005	USD
CY2013Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		USD
CY2012Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	637182	USD
CY2013Q2	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	746	USD
CY2012Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	404	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.34
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.17
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.09
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-17786	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents		USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-27854	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	52343	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	628630	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	689452	USD
CY2012Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue		USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-198401	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-85435	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	398772	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	28344	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		USD
CY2012Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	637182	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-10880	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-41917	USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
CY2013Q2	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
CY2012Q2	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments	1033004	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	69178	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1102182	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1349081	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	802273	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	499034	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	290668	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9510628	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3440968	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2014259	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1256341	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-550365	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21091969	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	240776	USD
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	400523	USD
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	166540	USD
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	560682	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	228272	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	5821	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	419	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	26007	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	7509	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	16000	USD
CY2013Q2	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	9425	USD
CY2012Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	8867	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	91860	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1155956	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4846300	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5294851	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	446024	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	644425	USD
CY2013Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	241052	USD
CY2012Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	872413	USD
CY2013Q2	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	228272	USD
CY2012Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	228272	USD
CY2013Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	803372	USD
CY2012Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	200311	USD
	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><!--StartFragment--> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr valign="top"> <td style="WIDTH: 27pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> a.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: justify"> General:</div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 8.1pt; text-align: left; TEXT-INDENT: 0pt"> Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd. ("Hadasit") (the "First Agreement") to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, see also note 2a.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: -2.85pt; text-align: left; TEXT-INDENT: 0pt"> In February 2013, the Company's common stock began trading on The Nasdaq Capital Market under the symbol ORMP.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the "Subsidiary"), (together with the Company, "the Group").</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with the ASC Topic 915 "Development Stage Entities" due to the fact that it has not generated any revenues from its operations.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"> Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"> Based on its current cash resources and commitments, and cash received in private offerings in the year ended August 31, 2012 and the nine month period ended May 31, 2013 (see note 4b), the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months. See also note 6 with respect to the Company registered direct offering.</div> <!--EndFragment--></div> </div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1450936	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16942875	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1643828	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1745762	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1809579	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3115165	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1959262	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14000545	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3440968	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2014259	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1256341	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-550365	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21332745	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4478917	USD
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-2769271	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-2760474	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-2977376	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-1561245	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-3344478	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3326339	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1946688	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1334670	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-540420	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21455456	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	84010	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-38967	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-15869	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	84010	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	131924	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax		USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-112584	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-15869	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	131924	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	69178	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax		USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	18491	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax		USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	69178	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	117092	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax		USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-55126	USD
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax		USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	117092	USD
CY2012Q3	us-gaap	Other Liabilities Fair Value Disclosure OtherLiabilitiesFairValueDisclosure	637182	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	338267	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	39294	USD
CY2013Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	6265	USD
CY2012Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	10251	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	718647	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	223638	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	14834	USD
CY2013Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	84594	USD
CY2012Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	306	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	430796	USD
CY2013Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	178800	USD
CY2012Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	84642	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	628630	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1		USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	628630	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2013Q2	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2012Q2	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	434876	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	43111	USD
CY2013Q2	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
CY2012Q2	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	381666	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	3023	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2109	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	9918	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4659	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2129	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	130271	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1862817	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	500000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	7766552	USD
CY2013Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	12780	USD
CY2012Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	6959	USD
CY2013Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	62302	USD
CY2012Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2307	USD
CY2013Q2	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	7362	USD
CY2012Q3	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	4740	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1450936	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	16595571	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	120000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><!--StartFragment--> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr valign="top"> <td style="WIDTH: 27pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> d.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: justify"> Reclassifications</div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"> Certain figures in respect of prior years have been reclassified to conform to the current year presentation.</div> <!--EndFragment--></div> </div>
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	275000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	66243	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	1800000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	5428000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	226671	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	450000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	676671	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5730	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4768	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	120000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1977258	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1144415	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	835636	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	249752	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11509952	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2012Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21332745	USD
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17891777	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	627511	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	154199	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5598798	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	4159224	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7223377	shares
CY2002Q2	us-gaap	Stockholders Equity StockholdersEquity	53700	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	3723916	USD
CY2007Q3	us-gaap	Stockholders Equity StockholdersEquity	513131	USD
CY2008Q3	us-gaap	Stockholders Equity StockholdersEquity	4593060	USD
CY2009Q3	us-gaap	Stockholders Equity StockholdersEquity	2746192	USD
CY2010Q3	us-gaap	Stockholders Equity StockholdersEquity	830272	USD
	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	12	pure
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	77779	USD
CY2008	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	275000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1422592	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2122981	USD
CY2008	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5784800	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3694212	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2944464	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	434876	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7087831	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5850679	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5860320	shares

Files In Submission

Name	View Source	Status
0001178913-13-002087-index-headers.html	Edgar Link	pending
0001178913-13-002087-index.html	Edgar Link	pending
0001178913-13-002087.txt	Edgar Link	pending
0001178913-13-002087-xbrl.zip	Edgar Link	pending
exhibit_31-1.htm	Edgar Link	pending
exhibit_31-2.htm	Edgar Link	pending
exhibit_32-1.htm	Edgar Link	pending
exhibit_32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
ormp-20130531.xml	Edgar Link	completed
ormp-20130531.xsd	Edgar Link	pending
ormp-20130531_cal.xml	Edgar Link	unprocessable
ormp-20130531_def.xml	Edgar Link	unprocessable
ormp-20130531_lab.xml	Edgar Link	unprocessable
ormp-20130531_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zk1313391.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2013 Q3 Form 10-Q Financial Statement

#000117891313002087 Filed on July 17, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2013 Q3 Form 10-Q Financial Statement

#000117891313002087 Filed on July 17, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp